Showing results (81-90 of 99) with videos related to
Sort By:
Pageof 10
Molecular Immunology|May 16, 2006
A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSFEva-Maria Krinner, Tobias Raum, Silke Petsch, et al.Transplant Immunology|June 29, 2011
The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well toleratedChristine Plater-Zyberk, Dave M Lopes Estêvão, Sandrine d'Argouges, et al.Mabs|January 12, 2010
Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cellsJutta Steigerwald, Tobias Raum, Stefan Pflanz, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 18, 2009
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine releaseMaria Amann, Sandrine D'Argouges, Grit Lorenczewski, et al.Blood|December 5, 2013
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330Christina Krupka, Peter Kufer, Roman Kischel, et al.Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cellsRalf Lutterbuese, Tobias Raum, Roman Kischel, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 4, 2009
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEARalf Lutterbuese, Tobias Raum, Roman Kischel, et al.Molecular Cancer Therapeutics|October 9, 2012
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigensMatthias Friedrich, Tobias Raum, Ralf Lutterbuese, et al.Blood|May 18, 2012
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabMatthias Klinger, Christian Brandl, Gerhard Zugmaier, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid TumorsMary Ellen Molloy, Richard J Austin, Bryan D Lemon, et al.Pageof 10